Focused On-demand Library for Gem-associated protein 5

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.







Alternative names:


Alternative UPACC:

Q8TEQ6; Q14CV0; Q8WWV4; Q969W4; Q9H9K3; Q9UFI5


Gem-associated protein 5 plays a pivotal role in the assembly of small nuclear ribonucleoproteins (snRNPs), essential for pre-mRNA splicing. This process is crucial for the accurate expression of genetic information. The protein facilitates the formation of the spliceosome by catalyzing the assembly of snRNPs, which are integral to the splicing of cellular pre-mRNAs. Its ability to bind to the 7-methylguanosine cap of RNA molecules and regulate the translation of SMN1 mRNA highlights its multifaceted role in RNA metabolism.

Therapeutic significance:

The protein is linked to Neurodevelopmental disorder with cerebellar atrophy and motor dysfunction, a condition characterized by developmental delays, motor abnormalities, and cognitive impairment. Understanding the role of Gem-associated protein 5 could open doors to potential therapeutic strategies for this disorder, emphasizing the importance of targeted research in unraveling its biological functions and therapeutic potential.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.